PCV13 prevents invasive pneumococcal disease in children
At least one dose of the 13-valent pneumococcal conjugate vaccine (PCV13) has high individual vaccine effectiveness (VE) in preventing invasive pneumococcal disease (IPD) in a paediatric population with suboptimal vaccination coverage, a new study has shown.
Written medical records of 169 paediatric IPD patients (median age 27 months; 37.9 percent female) and 645 age-, sex-, hospital-, date of hospitalization- and underlying disease-matched controls (median age 29 months; 38.4 percent female) in a 1:4 ratio were used in this study. Those whose samples were insufficient for reliable serotyping of Streptococcus pneumoniae were excluded.
Vaccination status was determined from medical records, health cards or vaccination records. Those who received PCV13 after six weeks of age and at least 15 days prior to hospitalization were included. Those with unknown vaccination status were also excluded.
Against all PCV13 serotypes, at least one dose of the PCV13 vaccine showed good VE (75.8 percent; 95 percent CI, 54.1 to 87.2 percent; p<0.001) after adjusting for confounders. This was consistent in children between 7 and 23 months (VE, 80.7 percent; 45.3 to 93.2 percent; p=0.002), and 24 to 59 months (VE, 75.3 percent; 45.4 to 88.9 percent; p=0.001).
Similarly, at least one dose of the PCV13 vaccine showed good VE against PCV13-non-PCV7 serotypes (VE, 64.2 percent; 31.9 to 81.2 percent; p=0.002). However, subgroup analysis revealed that only those aged 24 to 59 months experienced significant VE (66.9 percent; 28.6 to 84.7 percent; p=0.005).
At least one dose of PCV13 also showed significant VE against all PCV13 serotypes (VE, 95.8 percent; 84.0 to 98.9 percent; p<0.001) and all PCV13-non-PCV7 serotypes (VE, 95.7 percent; 75.7 to 99.3 percent; p<0.001) excluding serotype 3.